TIRmed Pharma´s proprietary compound to treat inflammatory skin disorders was issued patent approval in the US, April 21st, 2020.
- TIRmed Pharma raises 5.4 MSEK in equity to continue pursuing preclinical development of new antiviral treatment and a topical treatment for atopic eczema.
- New publication
- TIRmed Pharma receives approval to grant patents in Europe
- TIRmed Pharma receives approval of patent in the US
- TIRmed Pharma receives SME Instrument Phase 1 grant from EU Grant No 885787-TIR-C